8.30 |
Reception |
| |
Regulatory Requirements |
| | | |
9.00 |
Experience with novel radionuclides in radiopharmacy |
Serge Lyashchenko, (MSKCC, New York, USA) | |
9.30 |
A bumpy road to standardize and harmonize the regulatory requirements for radiopharmaceutical production involving novel radionuclides |
Clemens Decristoforo (Medical University Innsbruck) | |
10.00 |
Open discussion |
Clemens Decristoforo | |
10.30 |
Short break with poster session |
| |
Industrial Collaboration |
| | | |
11.00 |
TBC |
Przemysław Kozanecki, CEO, Synektik Pharma Sp. z o.o. | |
11.30 |
New Voxel Innovation Campus – challenges and perspectives for Polish radiopharmaceutical community |
Marek Pilch-Kowalczyk, Technology Advisor, Voxel SA | |
12.00 |
NCBJ Radioisotope Centre POLATOM in the logistics of radioactive goods |
Monika Koczyk, NCBJ Logistics Manager | |
12.30 |
TBC |
Tomasz Ciach, Warsaw University of Technology | |
13.00 |
Lunch |
| |
Results from the user projects enabled by PRISMAP |
| | | |
14.30 |
General overview of theranostics impact in oncology |
Jolanta Kunikowska, Warsaw Medical University | |
15.00 |
Translational investigations of new PSMA-targetting radiobioconjugates based on theranostic Pb-203 and Pb-212 (tentative) |
Marc Pretze, Constantin Mamat, Carmen Waengler (U. Dresden, U. Heidelberg) | |
15.30 |
Break |
| |
16.00 |
Manganese-52 for applications on multiple coincidence detection in Positron Emission Tomography |
Pawel Moskal (Jagiellonian University in Krakow, Poland) - TBC | |
16.30 |
New in-vivo models and new radionuclides for efficient evaluation of targeted radionuclide therapy |
Clement Morgat (U. Bordeaux) | |
17.00 |
Treatment Efficacy of 161Tb-Labeled GRPR Ligands in Comparison with their 177Lu-Labeled Analog |
Thomas Guenther (Stanford University, USA) | |
17.30 |
End of the meeting |
| |